Asset
IPILIMUMAB
TriSalus Life Sciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04935229 | phase1 | terminated | 2021-08-02 | 2024-07-17 | TriSalus Life Sciences, Inc. | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma |
| NCT05220722 | phase1_2 | terminated | 2022-03-02 | 2024-07-31 | TriSalus Life Sciences, Inc. | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors |
FDA applications (0)
This company has no applications containing this asset.